Companies: 10,795·Total market cap: $144.5T
GRI Bio, Inc.

GRI Bio, Inc.

GRINASDAQHealthcare● Active
$2.17
+$0.17(+8.50%)
Market Cap$194935
P/E Ratio
52W High$80.36
52W Low$1.97

GRI Bio, Inc. (GRI) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

gri · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for GRI Bio, Inc. (GRI) measures how much investors pay for each dollar of the company's trailing earnings. GRI's current PE ratio of N/A is calculated by dividing its stock price of $2.17 by its TTM earnings per share of -$8.79.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2026 est. EPS $-4.77
Based on 2 analysts
EPS (TTM)
-$8.79
TTM · diluted EPS
PEG Ratio
-0.00
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · GRI Bio, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2018 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
GRI Bio, Inc.
GRI Bio, Inc.You
GRI
$0MN/A-$8.79
Abpro Corporation
Abpro Corporation
ABP
$1MN/A-$23.09
Biodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals Plc
BDRX
$1MN/A-$113.82
Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd.
CANF
$2MN/A-$12.02
Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics, Inc.
CLDI
$1MN/A-$4.63
CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals, Inc.
CNSP
$3MN/A-$35.75
Genprex, Inc.
Genprex, Inc.
GNPX
$1MN/A-$17.40

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 8 of 8 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-121.80
2024-12-31
FY2024
$-1253.74
2023-12-31
FY2023
$-8261.72
2022-12-31
FY2022
$-2773.28
2021-12-31
FY2021
$-801.84
2020-12-31
FY2020
$-2840.63
2019-12-31
FY2019
$-3888.32
2018-12-31
FY2018
$-4840.23

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for GRI Bio, Inc. (GRI) measures how much investors pay for each dollar of the company's trailing earnings. GRI's current PE ratio of N/A is calculated by dividing its stock price of $2.17 by its TTM earnings per share of -$8.79.

PE Ratio = Stock Price ÷ EPS (TTM)
= $2.17 ÷ -$8.79 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

GRI pe ratio · 6 questions

GRI's current PE ratio is N/A as of 2026-06-09, based on a stock price of $2.17 and TTM EPS of -$8.79. Data sourced from Financial Modeling Prep via GRI's SEC 10-K and 10-Q filings.

GRI PE ratioWhat is GRI PE ratioCurrent PE ratio of GRIGRI PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · GRI Bio, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09